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AbSTRACT
Myositis ossificans progressiva is a rare autosomal dominant di-
sease with less than 1,000 case reports. Such patients present ede-
ma, caused by inflammatory processes that progressively calcify, 
and with loss of mobility in the region affected. The objective of 
INTRODUCTION
Myositis ossificans progressiva (MOP), also 
known as fibrodysplasia ossificans progressiva (FOP), 
is a rare disease with less than 1,000 cases described. 
It is an autosomal dominant condition that varies in 
prominence, with sporadic cases(1). The process of 
heterotopic bone formation involves tendons, fascias, 
aponeuroses and muscles.
It was described for the first time by Patin(2). Its 
physiopathology remains incompletely understood. The 
soft tissues become affected by edema, and the back 
of the neck is the region most frequently involved(3). 
This edema, from inflammatory processes, gradually 
becomes calcified, with loss of mobility in the affected 
region. Repeated trauma may trigger the process.
Many treatments have been used, such as steroids, 
isotretinoin and oral etidronate, but without good re-
sults(4-6). In vitro chemical studies have shown that 
bisphosphonates adsorb hydroxyapatite crystals, thus 
diminishing heterotopic bone formation during the 
active stage of the disease(7). Palhares(8) observed that 
high doses of ascorbic acid controlled the progression 
of the disease.
The aim of this study was to report on a case of 
MOP, present the clinical manifestations and discuss 
the treatments available.
CASE REPORT
The patient was a 21-year-old man who was atten-
ded at the Department of Orthopedics of the Clinical 
Hospital of the School of Medicine, Federal Universi-
ty of Goiás. He had presented hardened tumor growths 
and deformities since birth, but they had worsened 
greatly during his adolescent growth, from the age 
of eight years onwards. He complained of pain and 
movement difficulties, along with short thumbs.
He presented multiple contractures in his upper 
limbs, lower limbs and spine. His posture was sco-
liotic, with a high degree of thoracic lordosis, dorso-
lumbar stiffness and cervical stiffness. His left scapula 
was protruded, and he had ectopic ossifications in 
the paravertebral musculature. He had difficulty in 
opening his mouth, swallowing food and performing 
thoracic inspiration.
His hips and shoulders were stiff bilaterally, with 
atrophied deltoid, trapezoid, biceps, triceps, middle 
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gluteus and quadriceps muscles. He also presented 
major limitation of elbow and ankle flexion-exten-
sion. His gait was equine, with knee contracture, such 
that the right knee was stiff in flexion and left knee 
in extension.
Laboratory blood tests for calcium, phosphorus, 
alkaline phosphatase, urea, creatinine and parathyroid 
hormone found normal values. Imaging examina-
tions (radiographs) showed several calcified lesions, 
heterotopic ossifications and bone bars in the lum-
bar spine (Figure 1A), cervical spine (Figure 1B), 
thoracic spine (Figure 2), pelvis (Figure 3) and knee
(Figure 4 A and B).
Figure 1 – Anteroposterior radiograph of the lumbar spine (A) and 
cervical spine (B), showing paravertebral calcifications. 
A B
Figure 2 – Anteroposterior radiograph of the chest showing ectopic 
calcifications that limit thoracic inspiration.
Figure 3 – Anteroposterior radiograph of the pelvis showing periar-
ticular muscle calcification.
Figure 4 – Anteroposterior radiograph (A) and lateral radiograph (B) 
of the right knee, showing calcifications that lead to joint stiffness. 
A B
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The treatment instituted was clinical, consisting of 
guidance to avoid trauma and referral for bisphospho-
nate and ascorbic acid therapy. 
DISCUSSION
Correct early diagnosis of MOP is essential in or-
der to allow appropriate management to start. Un-
necessary biopsies and surgery should be avoided, 
as should intramuscular or intravenous injections, 
which might trigger or accelerate the inflammatory 
process, a phase that precedes ectopic calcifications. 
Intramuscular vaccines such as against diphtheria-
-tetanus-pertussis, measles, hepatitis-B, etc, can be 
applied subcutaneously(9). Dental treatment should be 
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done cautiously, avoiding anesthesia, particularly in 
the mandible, in order to prevent ankylosis of the tem-
poromandibular joint(10). Prophylaxis for dental caries 
is essential in order to avoid procedures that would 
be more aggressive. The physical activity that is most 
appropriate for MOP patients is swimming, even if 
with some limitations, since patients can adapt to the 
movements that they are still able to make. Thus, this 
is a means of doing physical exercise without the le-
sions resulting from impacts or direct trauma.
MOP can be seen on simple radiographs approxima-
tely two to four weeks after the process starts. The cal-
cification starts on the periphery and progresses towards 
the center, which differentiates it from osteosarcoma. 
Computed tomography helps to delineate the central 
radiolucent area surrounded by peripheral density, in 
cases of MOP(11).
The differential diagnosis is made with universal 
idiopathic calcinosis, dermatomyositis, tumoral idio-
pathic calcinosis and diseases due to changes in cal-
cium metabolism. The presence of ossifications in the 
soft tissues of the axial skeleton and abnormalities in 
the fingers simplifies the diagnosis in cases of MOP.
Ascorbic acid seems to act in MOP cases towards 
stabilizing the disease(8). Diminished ossification, 
possibly in transition, i.e. still within the inflam-
matory process, has been attributed to the action of 
ascorbic acid towards modulating the synthesis of 
procollagen III(8). 
Regarding the treatments used so far, bisphospho-
nates are effective in relation to ossification that has 
already become established(12). When there is a severe 
limitation on movements and gastric intolerance, use 
of intravenous bisphosphonate may be indicated and 
may produce a good improvement(12,13).
Oral or intravenous administration of ascorbic acid 
and bisphosphonate may be an alternative for con-
trolling and diminishing ectopic calcifications over 
the long term, thereby significantly improving these 
patients’ quality of life.
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